Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

While Gilead Sciences’ HIV prevention drug lenacapavir got approved by the US FDA, its made-in-India generic versions may be ...

The U.S. Food and Drug Administration has approved a groundbreaking HIV prevention shot that only needs to be taken twice a year. Medical experts are calling it one of the most significant ...

The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...

The new HIV PrEP option could drastically reduce the number of new cases by offering a new alternative to daily pills or every-other-month injections.

The US Food and Drug Administration (FDA) has approved a new shot to prevent HIV, offering a long-acting alternative to daily ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.

The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most ...